Enroll Enroll

Enroll your patients in the Hub to access THIOLA® (tiopronin) tablets

For some people with cystinuria, making therapeutic lifestyle changes such as drinking more water, reducing protein and sodium intake, and adjusting the pH levels of their urine may not be enough to stop cystine stones from forming. If your patients have made therapeutic lifestyle changes and are still forming cystine stones, THIOLA can help.1-3

Getting THIOLA for patients with cystinuria is easy. Download and complete the THIOLA Total Care Hub enrollment form to get started today. For any questions or help with the enrollment forms, call 844-4-THIOLA (844-484-4652).

Get started

Access Access

Gain access to insurance coverage

The Total Care Hub is ready to help streamline the insurance verification and approval process for patients. Upon joining the Hub, patients can tap into different Hub services for easy and convenient access to THIOLA.

Hub Counselor

A dedicated Hub Counselor will work with insurance companies to assist with benefit verification, prior authorizations, and appeals.


The Total Care Hub will partner with your office staff to help organize relevant documentation throughout treatment.

Maintaining therapy

Patients will receive guidance to ensure no interruption in therapy during changes in marital, employment, or disability status.

Financial assistance

Co-pay assistance,a reimbursement, and patient assistance programs are available for eligible patients.

aPertains to commercial insurance.

Download and complete the THIOLA Total Care Hub enrollment form for your patient today.

Get started

Delivery Delivery

Convenient delivery for optimal disease management

Adherence can be easy with the help of the Delivery Hub:

Picture of a patient receiving a THIOLA delivery
  • THIOLA prescriptions will be delivered directly to patients, saving trips to the pharmacy
  • THIOLA can be delivered in a convenient monthly care packet
  • Individuals can plan ahead and manage refills so that a dose is never missed
  • Prescheduled refill delivery is available for those who are eligible
Support Support

Live, on-demand support at any time

Available 24 hours a day, 7 days a week, a Hub representative can:

Answer questions about treatment.

Set up refills and appointment reminders.

Connect patients with a Hub pharmacist to answer questions about THIOLA.

References:  1. Pareek G, Steele TH, Nakada SY. Urological intervention in patients with cystinuria is decreased with medical compliance. J Urol. 2005;174(6):2250-2252.  2. THIOLA [package insert]. San Antonio, TX: Mission Pharmacal Company.  3. Knoll T, Zöllner A, Wendt-Nordahl G, Michel MS, Alken P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol. 2005;20(1):19-24. doi:10.1007/s00467-004-1663-1.  

INDICATIONS: THIOLA® (tiopronin) tablets are indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine  >500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine.

Important Safety Information 

CONTRAINDICATIONS: THIOLA is contraindicated during pregnancy (except where the benefits clearly outweigh the risks), in nursing mothers, and in patients who have previously developed agranulocytosis, aplastic anemia or thrombocytopenia while on this medication.


  • While no deaths have been reported with THIOLA treatment, THIOLA can potentially cause all the serious adverse reactions reported for d-penicillamine, including death. 
  • Hematologic abnormalities requiring drug discontinuation may occur: inform patients to report promptly signs or symptoms of hematologic abnormalities.
  • Proteinuria, sometimes severe enough to cause nephrotic syndrome: monitor affected patients closely.
  • Discontinue THIOLA therapy if there are findings suggestive of Goodpasture’s syndrome, myasthenic syndrome, or myasthenia gravis. If pemphigus-type reactions occur, discontinue therapy and consider steroid treatment.
  • Inform patients about potential complications; advise them to promptly report any treatment-emergent signs or symptoms.
  • To reduce the risk of serious complications, the following tests should be conducted: 
    • Peripheral blood counts, direct platelet counts, hemoglobin, serum albumin, liver function tests, 24-hour urinary protein, routine urinalysis: 3-6 month intervals
    • Urinary cystine analysis: frequently during dose optimization, and at 6 month intervals thereafter
    • Abdominal roentgenogram: annually
  • In animal studies, THIOLA has been shown to cause fetal harm. THIOLA should only be used during pregnancy if the potential benefit justifies potential risk to the fetus.
  • THIOLA should not be used in nursing mothers.
  • The safety and efficacy of THIOLA in children under 9 years of age have not been established.


Adverse reactions associated with THIOLA include the following:

  • Drug fever during the first month
  • Generalized rash with pruritus
  • Lupus erythematous-like drug reaction (e.g., fever, arthralgia, lymphadenopathy, positive antinuclear antibody test)
  • Hypogeusia
  • Vitamin B6 deficiency (uncommon)
  • Wrinkling and friability of skin
  • Jaundice and abnormal liver function tests (in non-cystinuric conditions)

THIOLA is associated with fewer or less severe reactions than d-penicillamine, however the following adverse reactions may occur:  

  • Gastrointestinal (nausea, emesis, diarrhea, anorexia, abdominal pain, bloating, flatus)
  • Impairment in taste or smell
  • Dermatologic (pharyngitis, oral ulcers, rash, ecchymosis, pruritus, urticaria, warts, skin wrinkling, pemphigus, elastosis perforans serpiginosa)
  • Hypersensitivity reactions (laryngeal edema, dyspnea, respiratory distress, fever, chills, arthralgia, weakness, fatigue, myalgia, adenopathy)
  • Hematologic (increased bleeding, anemia, leukopenia, thrombocytopenia, eosinophilia)
  • Renal (proteinuria, nephrotic syndrome, hematuria)
  • Pulmonary (bronchiolitis, hemoptysis, pulmonary infiltrates, dyspnea)
  • Neurologic (myasthenic syndrome)

These reactions are more likely to occur during THIOLA therapy for patients who had previously shown toxicity to d-penicillamine.

Please see full Prescribing Information.